Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study | Synapse
September 16, 2024
Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Figure S1 shows the study design.
Ask AI
Helpful
Bookmark
Share
Ask AI
Helpful
Bookmark
Share
Cite This Study
Meric‐Bernstam et al. (Mon,) studied this question.